Company profile
EOM Pharmaceuticals Holdings, Inc.
OTC: IMUC · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ 32GM —SS 29
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, market scale · ↓ workforce scale, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$14.3M
Employees
3
as of 2026-08-21
Market cap
$25.3M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02017
Net income-$14.3M-$14.3M2017
Operating income-$21.2M-$21.2M2017
Total assets$7.0M$7.0M2017
Liabilities$2.4M$2.4M2017
Equity$4.6M$4.6M2017
Revenue trend
FY2011 – FY2017 · USD
FY11
FY11
FY12
FY13
FY15
FY15
FY16
FY17
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is EOM Pharmaceuticals Holdings, Inc.’s revenue?
EOM Pharmaceuticals Holdings, Inc. booked $0 in FY2017 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Sona Nanotech Inc.——Defence Therapeutics Inc.——Resverlogix Corp.——Barinthus Biotherapeutics plc39DRein Therapeutics Inc.36DOcumetics Technology Corp.——Neighbors
Bergen →Key facts
CEOIrach Taraporewala
SectorHealthcare
IndustryBiotechnology
HeadquartersMontvale, NJ
ExchangeOTC: IMUC
Employees3
IPO date2021-01-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.